Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus (Q41156168)

27 September 2017

1 reference

title

Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus (English)

1 reference

27 September 2017

author

Marie-Christine Alessi

1 reference

ORCID Public Data File 2021

author name string

Juhan-Vague I

series ordinal

1

1 reference

27 September 2017

Alessi MC

series ordinal

2

1 reference

27 September 2017

Vague P

series ordinal

3

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

28

1 reference

27 September 2017

issue

4

1 reference

27 September 2017

page(s)

371-380

1 reference

Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Relation between extent of coronary artery disease and blood viscosity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Haemostatic function in myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Fibrinogen: an important risk factor for atherothrombotic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Does weight loss reduce plasma fibrinogen?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Haemostatic measures in type 2 diabetic patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Fatty acids, fibrinogen and blood flow: a general mechanism for hyperfibrinogenemia and its pathologic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Platelet plasminogen activator inhibitor 1 in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Adipsin and complement factor D activity: an immune-related defect in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899608999095

10.3109/07853899608999095

21 January 2018

Identifiers

DOI

1 reference

27 September 2017

1 reference